Wechselwirkungen · Stalevo
Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Stalevo 100 mg/25 mg/200 mg film-coated tablets Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Stalevo 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-112322 · Präparat HOS-093651
Due to entacapone's affinity to cytochrome P450 2C9 in vitro (see section 5.2), Stalevo may potentially interfere with active substances whose metabolism is dependent on this isoenzyme, such as S-warfarin. However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R-warfarin increased on average by 18% [CI90 11– 26%]. The INR values increased on average by 13% [CI90 6–19%]. Thus, a control of INR is recommended when Stalevo is initiated for patients receiving warfarin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-06T10:34:00Z · SHA-256 efa438d75f473f63d3f59b043f928d6ef3dd686a6813356b7fc3207963682e9f · Passage 211570bfbed5d778f74ec3f3b99e49aac43f523753cda3085866d19b2530d74e · Zeichen 2264–2813 im Abschnitt